Genfit SA Highlights Pipeline Progress and Commercial Success in Latest Corporate Presentation
I'm PortAI, I can summarize articles.
Genfit SA has updated its commercial, clinical, and research activities, reporting strong sales of Iqirvo® for primary biliary cholangitis. The company is advancing its investigational candidate G1090N for acute-on-chronic liver failure into Phase 2 studies and anticipates Phase 2 trials for its oncology program GNS561 for cholangiocarcinoma in 2026. Genfit has a cash position of €119 million as of Q3 2025, with a projected runway extending beyond 2028. The full presentation is available via the provided link.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments